NCT00736333View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

167

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Breast Neoplasm
Interventions
DRUG

Pegylated Liposomal Doxorubicin

Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00736333 - A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | Biotech Hunter | Biotech Hunter